Featured 13F manager
Pfizer Inc.
New York, NY 4 processed 13Fs on this site · 2025 Q3–2026 Q2
- $170M
- 17 Positions
- 2026 Q2
- −28.9% QoQ
- Top 5 78.9%
Pfizer Inc. files a Form 13F. The latest book is 2026 Q2 at $170M, down 28.9% QoQ, led by Allogene Therapeutics, Celcuity, and Arvinas.
Portfolio
top 5 78.9% · top 10 95.7%
- ALLO - Allogene Therapeutics 27.6%
- CELC - Celcuity 17.3%
- ARVN - Arvinas 16.2%
- PYXS - Pyxis Oncology 11.4%
- WVE - Wave Life Sciences 6.4%
- BHVN - Biohaven 4.7%
- CRBU - Caribou Biosciences 4.6%
- Spero Therapeutics 3.1%
- ZNTL - Zentalis Pharmaceuticals 2.3%
- ORIC - Oric Pharmaceuticals 2.1%
- CRDF - Cardiff Oncology 1.8%
- ZURA - Zura Bio · CLASS A 1.7%
- Other 0.8%
AUM over time
Latest book
| ALLO - Allogene Therapeutics | 27.55% | Hold | 22,032,040 | $2.13 | $47M | — | — |
| CELC - Celcuity | 17.35% | Hold | 295,652 | $99.95 | $30M | — | — |
| ARVN - Arvinas | 16.24% | Hold | 3,457,815 | $8.00 | $28M | — | — |
| PYXS - Pyxis Oncology | 11.43% | Hold | 7,032,770 | $2.77 | $19M | — | — |
| WVE - Wave Life Sciences | 6.42% | Hold | 1,875,000 | $5.83 | $11M | — | — |
| BHVN - Biohaven | 4.70% | Hold | 505,645 | $15.83 | $8M | — | — |
| CRBU - Caribou Biosciences | 4.63% | Hold | 4,690,431 | $1.68 | $8M | — | — |
| Spero Therapeutics | 3.13% | Hold | 2,362,348 | $2.26 | $5M | — | — |
| ZNTL - Zentalis Pharmaceuticals | 2.26% | Hold | 953,834 | $4.04 | $4M | — | — |
| ORIC - Oric Pharmaceuticals | 2.09% | Reduce −92.2% | 372,904 | $9.53 | $4M | −4,407,497 | −$54M |
| CRDF - Cardiff Oncology | 1.77% | Hold | 2,411,575 | $1.25 | $3M | — | — |
| ZURA - Zura Bio · CLASS A | 1.69% | Reduce −81.0% | 538,841 | $5.35 | $3M | −2,300,072 | −$14M |
| AGMB - Agomab Therapeutics | 0.61% | Hold | 75,000 | $13.81 | $1M | — | — |
| BOLT - Bolt Biotherapeutics | 0.08% | Hold | 31,305 | $4.28 | $134K | — | — |
| NXTC - Nextcure | 0.04% | Reduce −71.1% | 44,347 | $1.65 | $73K | −109,007 | −$1M |
| DNA - Ginkgo Bioworks · CL A | 0.02% | Hold | 2,928 | $10.25 | $30K | — | — |
| Senseonics | 0.01% | Hold | 2,171 | $5.72 | $12K | — | — |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2026 Q1
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| QTTB - Q32 Bio | 0.31% | Exit | 0 | $7.25 | $737K | −101,618 | −$737K |
Filings history
4 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 17 | $170M | −28.9% | 13F-HR | 8/13/2026 | 000007800326000102 |
| 2026 Q1 | 18 | $239M | +1.3% | 13F-HR | 5/12/2026 | 000007800326000064 |
| 2025 Q4 | 18 | $236M | −46.0% | 13F-HR | 2/12/2026 | 000007800326000013 |
| 2025 Q3 | 21 | $437M | — | 13F-HR | 11/13/2025 | 000007800325000161 |
About
Pfizer Inc.
4 processed 13Fs on this site · 2025 Q3–2026 Q2